Klebsiella pneumoniae is one of the main opportunistic and common nosocomial pathogen that causes several extensive and often fatal infections (1). Antibiotics agent may become a difficult task, because K. pneumoniae is intrinsic resistant to several drugss (2). Besides that, K. pneumoniae possesses several mechanisms of antimicrobial resistance through mutations selection in genes of chromosomes or by acquisition of resistant determinants (3). K. pneumoniae easily acquires further resistance pathways to several antibiotics agent, even through the treatment course. Different mechanisms of resistance often exist simultaneously, thus conferring combined resistance (4). Carbapenems have recognized as the most potent beta lactams and widely utilized as the mainstay and empirical for the treatment extensive infections caused by MDR Klebsiella pneumoniae (5). Unfortunately, resistance of K. pneumoniae to carbapenem has now emerged and is spreading worldwide (6). Carbapenem resistance may result from production of carbapenemase enzymes or up-regulation of the efflux pumps (7). Carbapenemases can be divided into major molecular families, when have serine at their active location, referred as serine carbapenemases , which are derivatives of class D or A enzymes and when have at least one atom of zinc as cofactors for optimal activity of enzyme referred as (MBLs), which belong to class B (8). Over the last decade, an ever K. pneumoniae isolates growing number producing MBLs have been showed from several countries ensuring Iraq (9).